361 related articles for article (PubMed ID: 10733052)
1. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. Metrifonate in Alzheimer's Disease Trial.
Shikiar R; Shakespeare A; Sagnier PP; Wilkinson D; McKeith I; Dartigues JF; Dubois B
J Am Geriatr Soc; 2000 Mar; 48(3):268-74. PubMed ID: 10733052
[TBL] [Abstract][Full Text] [Related]
2. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group.
Jann MW; Cyrus PA; Eisner LS; Margolin DI; Griffin T; Gulanski B
Clin Ther; 1999 Jan; 21(1):88-102. PubMed ID: 10090427
[TBL] [Abstract][Full Text] [Related]
4. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Cummings JL; Cyrus PA; Bieber F; Mas J; Orazem J; Gulanski B
Neurology; 1998 May; 50(5):1214-21. PubMed ID: 9595966
[TBL] [Abstract][Full Text] [Related]
5. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
6. Metrifonate for Alzheimer's disease.
López-Arrieta JM; Schneider L
Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
[TBL] [Abstract][Full Text] [Related]
7. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials.
Farlow MR; Cyrus PA
Dement Geriatr Cogn Disord; 2000; 11(4):202-11. PubMed ID: 10867446
[TBL] [Abstract][Full Text] [Related]
8. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
9. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT).
McKeith IG
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():2-7. PubMed ID: 9718228
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden.
Feldman H; Gauthier S; Hecker J; Vellas B; Emir B; Mastey V; Subbiah P;
J Am Geriatr Soc; 2003 Jun; 51(6):737-44. PubMed ID: 12757558
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.
Cummings JL; Nadel A; Masterman D; Cyrus PA
J Geriatr Psychiatry Neurol; 2001; 14(2):101-8. PubMed ID: 11419566
[TBL] [Abstract][Full Text] [Related]
12. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
13. Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.
Kaufer D
Dement Geriatr Cogn Disord; 1998; 9 Suppl 2():8-14. PubMed ID: 9718229
[TBL] [Abstract][Full Text] [Related]
14. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1998 Mar; 12(1):54-7. PubMed ID: 9539412
[TBL] [Abstract][Full Text] [Related]
15. Metrifonate enhances the ability of Alzheimer's disease patients to initiate, organize, and execute instrumental and basic activities of daily living.
Gélinas I; Gauthier S; Cyrus PA
J Geriatr Psychiatry Neurol; 2000; 13(1):9-16. PubMed ID: 10753002
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease.
Becker RE; Colliver JA; Markwell SJ; Moriearty PL; Unni LK; Vicari S
Alzheimer Dis Assoc Disord; 1996; 10(3):124-31. PubMed ID: 8876775
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease.
Pettigrew LC; Bieber F; Lettieri J; Wermeling DP; Schmitt FA; Tikhtman AJ; Ashford JW; Smith CD; Wekstein DR; Markesbery WR; Orazem J; Ruzicka BB; Mas J; Gulanski B
J Clin Pharmacol; 1998 Mar; 38(3):236-45. PubMed ID: 9549662
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease.
Frakey LL; Salloway S; Buelow M; Malloy P
J Clin Psychiatry; 2012 Jun; 73(6):796-801. PubMed ID: 22687392
[TBL] [Abstract][Full Text] [Related]
19. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
[TBL] [Abstract][Full Text] [Related]
20. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]